Mogamulizumab is a C–C chemokine receptor type 4 (CCR4)-directed monoclonal antibody used for the treatment of relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS), and adult T-cell leukemia/lymphoma (ATLL). This evidence concerns the gene CCR4 and adult T-cell leukemia/lymphoma.